Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain ...
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Company Research
Source: Yahoo! Finance
binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) IL-18 BPR was linked to Sonnet's proprietary tumor targeting F H AB platform, with or without single-chain wild-type IL-12 The bifunctional SON-1411 molecule is manufactured in Chinese Hamster Ovary (CHO) cells, while the monofunctional SON-1400 molecule is made in E. coli ; both have been highly purified and were bioactive in the receptor binding assays IL-18 BPR and IL-12 could be combined for broad applications in oncology and cell-based therapies PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the generation and in vitro characterization of two novel drug candidates, SON-1411 (IL18 BPR -F H AB-IL12) and SON-1400 (IL18 BPR -F H AB), each containing a modified version of recombinant hu
Show less
Read more
Impact Snapshot
Event Time:
SONN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SONN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SONN alerts
High impacting Sonnet BioTherapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SONN
News
- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds [Yahoo! Finance]Yahoo! Finance
- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross ProceedsGlobeNewswire
- Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 DomainGlobeNewswire
- Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.MarketBeat
SONN
Sec Filings
- 6/20/24 - Form 8-K
- 6/14/24 - Form 8-K
- 6/13/24 - Form 8-K
- SONN's page on the SEC website